Grupo para la caracterización molecular de las neoplasias hematológicas
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublications en collaboration avec des chercheurs de Memorial Sloan Kettering Cancer Center (12)
2023
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
-
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 12, pp. 811-818
2022
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2020
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2018
-
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
New England Journal of Medicine, Vol. 378, Núm. 12, pp. 1107-1120
2017
-
Second primary malignancies in multiple myeloma: An overview and IMWG consensus
Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Nature Genetics, Vol. 46, Núm. 2, pp. 107-115
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548